Pharmagen Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmagen has 517.08 million shares outstanding.
| Current Share Class | 517.08M |
| Shares Outstanding | 517.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +21.31% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | -0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.10
| Current Ratio | 0.10 |
| Quick Ratio | 0.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.79 |
| Interest Coverage | -0.74 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -58.91% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 31.96% |
| Weighted Average Cost of Capital (WACC) | 70.32% |
| Revenue Per Employee | 183,799 |
| Profits Per Employee | -267,851 |
| Employee Count | 24 |
| Asset Turnover | 1.85 |
| Inventory Turnover | 9.47 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.34 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 51.03 |
| Average Volume (20 Days) | 19,059 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.87 |
Income Statement
In the last 12 months, Pharmagen had revenue of 4.41 million and -6.43 million in losses. Loss per share was -0.02.
| Revenue | 4.41M |
| Gross Profit | 2.75M |
| Operating Income | -2.24M |
| Pretax Income | -5.87M |
| Net Income | -6.43M |
| EBITDA | -2.13M |
| EBIT | -2.24M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 264,673 in cash and 3.39 million in debt, with a net cash position of -3.13 million or -0.01 per share.
| Cash & Cash Equivalents | 264,673 |
| Total Debt | 3.39M |
| Net Cash | -3.13M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -7.80M |
| Book Value Per Share | -0.02 |
| Working Capital | -7.46M |
Cash Flow
In the last 12 months, operating cash flow was -483,093 and capital expenditures -102,607, giving a free cash flow of -585,700.
| Operating Cash Flow | -483,093 |
| Capital Expenditures | -102,607 |
| Free Cash Flow | -585,700 |
| FCF Per Share | -0.00 |
Margins
Gross margin is 62.27%, with operating and profit margins of -50.83% and -133.10%.
| Gross Margin | 62.27% |
| Operating Margin | -50.83% |
| Pretax Margin | -133.10% |
| Profit Margin | -133.10% |
| EBITDA Margin | -48.31% |
| EBIT Margin | -50.83% |
| FCF Margin | n/a |
Dividends & Yields
Pharmagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.65% |
| Shareholder Yield | -8.65% |
| Earnings Yield | -1,243,408.70% |
| FCF Yield | -113,288.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharmagen has an Altman Z-Score of -19.71 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -19.71 |
| Piotroski F-Score | 3 |